Advanced in Adult T-Cell Leukemia

Jing H. Pan

State Key Laboratory Of Experimental Hematology, 
Beijing, CN 
Advanced in Adult T-Cell Leukemia
State Key Laboratory Of Experimental Hematology, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Jing Pan practices in Beijing, China. Ms. Pan is rated as an Advanced expert by MediFind in the treatment of Adult T-Cell Leukemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Cervicitis, Bone Marrow Transplant, and Laryngectomy.

Her clinical research consists of co-authoring 151 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Adult T-Cell Leukemia.

Gender
Female

Locations

State Key Laboratory Of Experimental Hematology, Beijing, China
Other Locations
Hefei, China
Tongzhou, China
Nanjing, 210002, China
Drylands Salinization Research Station, China
Xining, China
Key Laboratory Of Natural Products Synthetic Biology Of Ethnic Medicinal Endophytes, Key Laboratory Of Chemistry In Ethnic Medicinal Resources, Kunming, China
Changchun, China
Lanzhou, China
Chongqing, China
Langfang, China
Xingtai, China
Head and Neck Surgery, Tianjin Union Medical Center
Tianjin, China
Hunan Key Laboratory Of Super Microstructure And Ultrafast Process, State Key Laboratory Of Powder Metallurgy, Changsha, 410083, China
Taiyuan, 030032, China
Harbin, 150040, China
Huainan, 232000, China
Shijiazhuang, 050051, China
Hubei Key Laboratory Of Tumor Microenvironment And Immunotherapy, Xiaoxita, China
Wenzhou, China
Zhengzhou, 450000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

151 Total Publications

Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity.
Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity.
Journal: Journal for immunotherapy of cancer
Published: September 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pan's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile